INTRODUCTION
The enzymic complex formed between the procoagulant serineprotease-activated Factor VII (FVIIa) and the integral membrane protein tissue factor (TF) triggers the initiation of blood clotting [1] . The action of the FVIIa-TF complex generates a burst of activated Factors IX (FIXa) and X (FXa) ultimately leading to formation of a stable fibrin clot [2, 3] . In i o, only approx. 1 % of Factor VII (FVII) exists as FVIIa [4] . At sites of vascular injury, FVIIa interacts with TF resulting in the rapid formation of the extrinsic complex [5] .
Steps involved in the conversion of FVII to a catalytically active FVIIa-TF complex are only partially understood. The initial event, cleavage of the peptide bond between Arg"&# and Ile"&$, converts the zymogen FVII into a two-chain serine protease that exists in equilibrium between a predominant zymogen-like form and an active FVIIa [6] [7] [8] [9] . In the zymogen-like conformation, the new N-terminus of Ile"&$ is solvent-exposed and accessible to modification, whereas in the active FVIIa, a salt bridge forms between the α-amino group of Ile"&$ and the β-carboxyl group of Asp$%$, stabilizing the insertion of Ile"&$ into the protein [10] . As inferred from studies on trypsinogen, the formation of this salt bridge orders the activation domain and shapes the S1 specificity pocket [11, 12] (nomenclature of Schechter and Berger [13] ). However, it is not well understood whether the exposure of extended macromolecular interaction sites (exosites) that are necessary for substrate recognition Abbreviations used : FVII, Factor VII ; FVIIa, activated FVII ; FVII : Ag, FVII antigen ; FVII :C, FVII coagulant activity ; FIX, Factor IX ; FIXa, activated FIX ; FX, Factor X ; FXa, activated FX ; ITS, insulin/transferrin/sodium selenite supplement ; PC, L-α-phosphatidylcholine ; PS, L-α-phosphatidylserine ; PCPS, 75 % (w/w) PC and 25 % (w/w) PS ; PEG 8000, poly(ethylene glycol) with a mean molecular mass of 8000 Da ; TAP, tick anticoagulant peptide ; TF, tissue factor ; TF/PC, TF after relipidation in PC. 1 To whom correspondence should be addressed (e-mail rItoso!hotmail.com).
N-terminus, is directly involved in the conversion of FVII into FVIIa. V154G FVII was exploited to study the FVII-TF interaction, together with three additional FVII variants that were expressed to serve as models for different FVII forms. The comparison of binding affinities of full-length TF after relipidation in -α-phosphatidylcholine for the zymogen FVII (Arg"&# Gln, K d l 1.04p0.27 nM), inactive FVIIa (Ser$%% Ala, K d l 0.27p0.06 nM) and a zymogen-like FVIIa (V154G, K d l 1.15p0.16 nM) supports the hypothesis that preferential binding of TF to active FVIIa is insufficient to drive the 10&-fold enhancement of FVIIa activity. In addition, the inability of V154G FVIIa to accommodate an inhibitor in the active site, indicating an improperly shaped specificity pocket, would explain the low activity of the zymogen-like form of FVIIa, which is predominant in the absence of TF.
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depends upon this rearrangement. Two-chain FVIIa shows poor activity towards both macromolecular and peptidyl substrates [14, 15] , possibly due to a predominant zymogen-like conformation in the absence of TF. TF dramatically enhances FVIIa activity (10&-fold) either by preferentially binding to the active form of FVIIa or by directly driving the conversion of zymogenlike FVIIa into active FVIIa when bound to the inactive form [7, 16] . TF may enhance FVIIa activity by exploiting a combination of these mechanisms. Understanding the mechanism by which TF can boost FVIIa catalytic efficiency may provide novel insights into designing alternative molecules for therapeutic aims in haemophilia and other bleeding disorders [17, 18] . Previous experimental assays used to study the binding of FVII to TF have been limited by the susceptibility of the zymogen FVII to autoactivation in the presence of TF and by inhibitors in the FVIIa active site that are known to constrain FVIIa in the active conformation [7, 19] .
In the present paper, we characterize a naturally occurring mutation, the substitution of glycine for Val"&% (V154G) at the P2h residue in the serine-protease domain of FVIIa (residue 17 in the chymotrypsin numbering system [20] ). This substitution creates a peculiar model of zymogen-like FVIIa, since V154G FVIIa cannot reach the active conformation even in the presence of TF. V154G FVIIa therefore represents a ' stable ' form of the FVIIa intermediate, which was exploited to study its interaction with TF compared with other FVII\FVIIa forms. The V154G FVIIa has also allowed us to analyse the competence of the specificity pocket in a zymogen-like form of FVIIa, and suggests the importance of the region proximal to the heavy chain N-terminus in the conversion from zymogen-like FVIIa into the active form. This aspect was further investigated by expressing and characterizing an alternate substitution of alanine for Val"&% (V154A) in FVII.
EXPERIMENTAL Materials
Hepes, poly(ethylene glycol) of a mean molecular mass of 8000 Da (PEG 8000) and Nunc cell factories were from Fisher Scientific (Pittsburgh, PA). -α-Phosphatidylcholine (PC), -α-phosphatidylserine (PS) and benzamidine were from Sigma (St. Louis, MO). N-Octyl β--glucopyranoside was from Calbiochem (La Jolla, CA) and Q Sepharose Fast Flow was from Pharmacia (Piscataway, NJ).
The chromogenic substrates methoxycarbonyl--cyclohexylglycyl-glycyl-arginine p-nitroanilide acetate (Spectrozyme f Xa), methanesulphonyl--cyclohexylalanyl-butyl-arginine p-nitroanilide acetate (Spectrozyme f VIIa), methylsulphonyl--cyclohexylglycyl-glycyl-arginine p-nitroanilide acetate (Spectrozyme fIXa) and the IMUBIND2 Factor VIIa ELISA kit were from American Diagnostica (Greenwich, CT). Stock solutions (approx. 5 mM) of these substrates were prepared in water and concentrations were determined using a molar absorption coefficient, ε $%# , of 8270 M −" : cm −" [21] . Insulin\transferrin\sodium selenite supplement (ITS) was purchased from Roche Diagnostics (Indianapolis, IN). The reaction buffer consisted of 20 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM CaCl # and 0.1 % (w\v) PEG 8000.
Phospholipid vesicles, composed of 75 % (w\w) PC and 25 % (w\w) PS (PCPS) were prepared as described in [22] and their concentration was determined by colorimetric phosphate analysis [22] .
Proteins
Plasma-derived human FVII, Factor IX (FIX) and Factor (FX), and human FIXa were from Haematologic Technologies Inc. (Essex Junction, VT). Plasma-derived FXa, soluble human TF (amino acid residues 1-219) and tick anticoagulant peptide (TAP), expressed in Pichia pastoris, were generously given by Dr Sai Kumar Buddai and Dr Sriram Krishnaswamy from the Children's Hospital of Philadelphia, PA. Recombinant Novoseven TM FVIIa was from Novo-Nordisk (Gentofte, Denmark). The ELISA kit to detect FVII was from Enzyme Research Laboratories (South Bend, IN). Full-length human TF made in insect cells was purchased from American Diagnostica (Greenwich, CT). Full-length and soluble human TF (amino acid residues 1-219), both produced in Escherichia coli, were kindly provided by Dr James H. Morrissey of the University of Illinois College of Medicine, Urbana-Champaign, IL. Full length human TF (25 µg) was reconstituted in 100 % (w\w) PC (1.4 mg) vesicles using 80 mM N-octyl β--glucopyranoside, as described in [23] , for reconstitution of TF in PCPS. The effective concentration of TF after relipidation in PC (TF\PC) was assumed to correspond to 50 % of the total concentration present due to the random orientation of TF during reconstitution [24] . This TF concentration was validated by titration experiments. Reconstituted TF was stored in the dark at 22 mC and used in experiments within 4 days of preparation. Ca# + -dependent anti-FVII monoclonal antibody was generously given by Dr Ulla Hedner of Novo-Nordisk, Gentofte, Denmark.
The γ-carboxyglutamic acid content of purified protein, which was determined by alkaline hydrolysis performed at Commonwealth Biotechnologies (Richmond, VA), verified full carboxylation of recombinant proteins.
Genomic studies and site-directed mutagenesis
FVII-exon and splicing-junction scanning was performed by direct sequencing as described in [25] . Population screening for the T)*'( G mutation, which results in the FVII mutant V154G, was performed by restriction analysis of an amplified genome fragment. Amplification of patient genomic DNA using the oligonucleotide primer 5h-AAACCCCAAGGCCGAACTG3h (corresponding to residues 8948-8966) created a new BsrI restriction site exclusively in the mutated sequence that results in a different pattern of enzymic digestion in the presence of the mutation from that in its absence (nucleotide numbering is according to FVII DNA sequence published by O'Hara et al. [26] ).
The substitutions Arg"&# Gln (R152Q), V154G, V154A, Asp$%$ His (D343H) and Ser$%% Ala (S344A) were introduced in FVII cDNA cloned in pCDNA3.1 vector (Invitrogen, San Diego, CA) using the QuikChange TM Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The presence of the point mutation was confirmed by DNA-sequence analysis of the entire FVII cDNA.
In vitro expression and purification of FVII recombinant proteins
HEK-293 cells were transfected using FuGene TM 6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN) or Lipofectamine 2000 (Gibco, Gaithersburg, MD) following the manufacturers' instructions. Cells were grown in Dulbecco's modified Eagle's medium\F12 in the presence of 10 % (v\v) foetal bovine serum, 5 µg\ml vitamin K, 2 mM -glutamine, 100 units\ml penicillin and 100 µg\ml streptomycin. Selection was performed as described in [27] . The highest producers (1.5-2 µg\ml per 10' cells over 24 h) were selected by ELISA, following the manufacturer's instructions, and further expanded to a cell-factory system using medium containing 10 µg\ml ITS. After 72 h, conditioned medium was collected at 24 h intervals. Benzamidine (10 mM) was added before filtering the medium through a 0.45 µm cellulose nitrate filter and the filtrate was frozen at k20 mC.
Purification of FVII from conditioned medium was carried out as described in [28] . The homogeneity of all protein preparations was evaluated by SDS\4-12 % PAGE [29] . FVII concentration was determined using a molecular mass of 50 000 kDa and a molar absorption coefficient, ε, of 69 500 M −" : cm −" .
FVII cleavage and functional assays
Recombinant FVII derivatives (2 µM) were incubated for 30 min in reaction buffer at 37 mC with 400 µM PCPS and 20 nM human FXa. TAP, at a concentration of 2 µM, was used to specifically inhibit FXa. The formation of two-chain FVIIa was evaluated by SDS\PAGE analysis after Coomassie Blue staining. 
Peptidyl substrate cleavage

Macromolecular substrate cleavage
Activity towards FX FVIIa (1 nM) was incubated in reaction buffer at 37 mC with 10 nM TF and 60 µM PC, or with 10 nM soluble TF and 100 µM PCPS ; the reaction was initiated by the addition of 100 nM human FX. Aliquots of the reaction were quenched at several time points up to 3.5 min in 20 mM Hepes, pH 7.4, 150 mM NaCl, 50 mM EDTA and 0.1 % (w\v) PEG 8000. The FXa chromogenic substrate (Spectrozyme fXa) was added at a final concentration of 100 µM. FXa activity was monitored by measuring the A %!& at 22 mC. The concentration of FXa formed as a function of time was determined by interpolation from the linear dependence of the initial rate of Spectrozyme fXa hydrolysis on known concentrations of FXa that were determined separately. The initial steady-state rate of FXa formation was determined from the slope of plots that documented the linear appearance of FXa with time. The same experiment was performed using different concentrations of FVIIa (1 or 10 nM) in the presence of soluble TF (10 or 100 nM respectively).
Activity towards FIX
FVIIa (1 nM) was incubated at 37 mC in reaction buffer with 200 nM soluble TF and 500 µM PCPS. The reaction was initiated by the addition of 400 nM human FIX. Aliquots of the reaction were quenched at several time points within 2 min in 30 mM EDTA and 60 % (v\v) ethylene glycol. FIXa activity was monitored at 405 nm after the addition of the chromogenic substrate Spectrozyme fIXa (500 µM). The concentration of FIXa that formed as a function of time was determined by interpolation from the linear dependence of the initial rate of Spectrozyme fIXa hydrolysis on known concentrations of FIXa that were determined separately. The initial steady-state rate of FIXa formation was determined from the slope of plots that documented the linear appearance of FIXa with time.
Carbamylation of FVIIa
FVIIa (4 µM), in the presence or absence of 20 µM soluble TF, was incubated with 0.2 M NaNCO at 22mC in reaction buffer, pH 7.2. Aliquots from the reaction were taken at 0, 15, 30, 60, 90, 120, 150 and 180 min. Residual activity of FVIIa towards Spectrozyme f VIIa (800 µM) was measured using 20 nM FVIIa, 100 nM soluble TF for wild-type ; 200 nM FVIIa, 1µM soluble TF for V154G FVIIa and 60 nM FVIIa, 300 nM soluble TF for V154A FVIIa.
In order to rule out the possibility that carbamylation affects TF cofactor activity, 2 µM soluble TF was incubated at 22mC in the absence or presence of 0.2 M NaNCO in reaction buffer, pH 7.2. After 0, 1 and 2 h time intervals, TF cofactor activity was tested using 100 nM soluble TF in the presence of 20 nM FVIIa, 100 µM PCPS in Reaction Buffer. The amidolytic activity of the soluble TF-FVIIa complex was assayed adding Spectrozyme f VIIa (375 µM).
FVII interaction with an active-site inhibitor
The ability of wild-type and mutated FVIIa to accommodate an inhibitor in the active site was tested using IMUBIND2 Factor VIIa ELISA kit that employs a biotinylated enzyme inhibitor of FVIIa and an anti-FVII\FVIIa monoclonal antibody as the capture antibody. The assay was performed following instructions of the manufacturer. Wild-type and Novoseven  FVIIa concentrations ranged from 0.031 nM to 2 nM, whereas V154G FVIIa concentrations ranged from 0.5 nM to 8 nM. The activesite inhibitor provided was a Phe-Pro-Arg chloromethylketone.
TF-binding competition assay for recombinant proteins
Novoseven TM FVIIa (10 nM) was incubated in Reaction Buffer and 100 µM PCPS, with different fixed concentrations of soluble TF (5, 
FVII autoactivation
The time course of wild-type FVII autoactivation was performed in reaction buffer using concentrations of the soluble TF-FVII complex above (100 nM FVII and 100 nM soluble TF in the presence of 2.5 nM FVIIa, either with or without 430 µM PCPS) and below (32 nM FVII and 30 nM soluble TF in the presence or absence of 2.5 nM FVIIa, either with or without 430 µM PCPS) the K d value we calculated in the present study. Aliquots of the reactions were tested for the amidolytic activity of the soluble TF-FVIIa complex at 0, 10, 20, 40, 60, 90 and 120 min by adding Spectrozyme fVIIa (375 µM).
Data analysis
Steady-state kinetic constants for synthetic substrate hydrolysis were determined from duplicate measurements of the initial velocity that were obtained using different substrate concentrations. Initial velocity data were fit to the Michaelis-Menten equation [30] by nonlinear least-squares regression analysis using the Marquardt algorithm [31] . When saturation of enzyme by substrate was not achieved (K m [S]), catalytic efficiency (k cat \K m ) was extracted with reasonable accuracy from the slope of the linear dependence of initial velocity on substrate concentration.
For competition experiments with the inactive FVII\FVIIa mutants, titration curves with different concentrations of TF were simultaneously analysed by fitting the initial velocity of synthetic peptide hydrolysis to the cubic Equation 17 of Olson et al. [32] as described in [33] . Nonlinear least-squares regression yielded values of ∆V, V t , K d , and n, which described the binding of Novoseven TM FVIIa to TF, and K dcomp and n comp , which described the equivalent interaction of inactive mutant FVIIa with TF. In these analyses ∆V is the decrease in velocity of substrate cleavage when competitor FVIIa concentration saturates the fixed concentration of TF ; V t is the velocity at infinite concentration of competitor, equal to the activity of the fixed concentration of Novoseven TM FVIIa in the absence of TF ; K d is the equilibrium dissociation constant for the FVIIa-TF interaction, and n represents the number of moles of FVIIa bound per mole of TF at saturation. According to previous results, in this analysis n was set at 1 [15] .
Reduction in activity after carbamylation was fitted to firstorder exponential decay through nonlinear least-squares regression analysis.
RESULTS
Identification and characterization of mutant FVII
Two asymptomatic patients from Northern Italy were referred for a prolonged prothrombin time ( 2 S.D. above the prothrombin time of the reference plasma) detected in pre-surgery screening. FVII antigen (FVII : Ag) and coagulant activity (FVII : C) levels were 125 %, and 60 % for patient 1, and 128 % and 51 % for patient 2, compared with pooled normal plasma respectively. A third patient, also of Italian descent, was referred for a mild bleeding tendency from childhood including recurrent epistaxis. His FVII : Ag and FVII : C values were 42 % and 1 % respectively. Genomic DNA was isolated, after obtaining informed consent, from leucocytes of the patients. Sequence analysis of exon 6 showed heterozygosity for a T)*'( G substitution in the three patients. This point mutation causes the V154G mutation. No additional mutations were found in the other FVII exons or promoter region. Patient 3 was also heterozygous for the substitution G to A at the fifth nucleotide of intron 7 (IVS7j5, FVII Lazio mutation) [25] . This mutation, which affects the donor splice site in intron 7 of FVII, determines the insertion of 37 bp in the mature mRNA. The frameshift, caused by the abnormal splicing, results in a premature termination of translation at residue 231, thus abolishing most of the C-terminal catalytic domain [34] . Population screening using a mutagenized primer that produced a BsrI site excluded the presence of the T)*'( G change, which is responsible for the V154G substitution, in 100 normal Italian subjects, thus indicating that this transversion is not a common polymorphism.
FVII mutants
The substitution V154A was expressed and characterized to test whether Gly"&% was responsible for the impaired salt-bridge formation in V154G FVIIa.
In order to compare the interaction of TF with V154G and different FVII forms, we expressed three additional representative FVII mutants, R152Q, D343H and S344A. R152Q FVII results in a molecule that cannot be cleaved, thus providing a stable zymogen form [27] ; D343H FVII is a naturally occurring substitution of the aspartic residue that is involved in salt-bridge formation, as reported in [35] , but is not yet characterized ; S344A FVII, owing to the substitution of the serine residue in the catalytic triad, leads to an inactive molecule that is properly cleaved and has normal TF-binding properties [16, 36] .
FVII proteolytic activation and FVIIa activity
Proteolytic activation of purified recombinant proteins was tested using human FXa. The cleavage pattern and rate of activation of 
Figure 1 Effect of carbamylation on FVIIa activity
Residual activity of FVIIa after carbamylation of the α-amino group of Ile 153 . NaNCO (0.2 M) was used to carbamylate 4 µM wild-type FVIIa (triangles), V154G FVIIa (circles) or V154A FVIIa (squares) in the presence (filled symbols) or absence (open symbols) of 20 µM soluble TF, at 22 mC in reaction buffer.
A
Figure 2 Binding of FVIIa to an active-site inhibitor
Interaction of FVIIa with a Phe-Pro-Arg chloromethylketone active-site inhibitor, detected by a horseradish peroxidase conjugated to streptavidin that recognized the biotinylated inhibitor-FVIIa complex (IMUBIND2 Factor VIIa ELISA). FVIIa concentrations ranged from 0.031 to 2 nM for Novoseven TM () and wild-type (>) FVIIa, whereas V154G FVIIa ($) concentrations ranged from 0.5 to 2 nM. Tissue factor binding to zymogen-like Factor VIIa wild-type, V154G, V154A, D343H and S344A FVII were indistinguishable, whereas R152Q was not cleaved after Arg"&#, even after a prolonged incubation for 4 h.
The resulting activated products were characterized with respect to their activity towards the FVIIa peptidyl substrate, Spectrozyme fVIIa, in the presence of soluble TF. The kinetic constants that were calculated for wild-type FVIIa were K m l 0.67p0.05 mM and k cat l 17. Whereas the catalytic efficiency parameters for wild-type, V154G and V154A FVIIa are shown in were characterized by undetectable activity towards FIX and FX. V154A FVIIa showed reduced proteolytic activity towards FX (1.4 nM FXa generated\min) as compared with wild-type FVIIa, and undetectable activity towards FIX, most probably owing to the low sensitivity of the chromogenic substrate for FIXa.
Carbamylation of Ile 153 in FVIIa
Previous studies have demonstrated that free FVIIa is susceptible to chemical modification of the exposed α-amino group of Ile"&$ by cyanate ions [7, 10] . In the presence of TF, structural rearrangements protect the FVIIa Ile"&$ N-terminus from carbamylation. Since carbamylation of Ile"&$ results in a loss of activity, the rate of modification of the N-terminus of FVIIa can be used to estimate the formation and the stability of the Ile"&$-Asp$%$ salt bridge [7] . Cyanate ions did not perturb TF-cofactor activity, as indicated by the unaltered capability of soluble TF to enhance FVIIa activity after carbamylation (results not shown).
In the presence of NaNCO, soluble TF protected wild-type and V154A FVIIa from carbamylation, whereas it failed to protect V154G FVIIa from inactivation beyond that seen with free enzyme (Figure 1 ). This finding suggests strongly that V154G maintains a zymogen-like conformation, even in the presence of TF.
FVII interaction with an active-site inhibitor
Wild-type or mutated FVIIa (2 nM and 8 nM respectively) was incubated with the active-site inhibitor Phe-Pro-Arg chloromethylketone ; whereas wild-type FVIIa showed normal binding of the inhibitor as compared with Novoseven TM FVIIa, V154G FVIIa was unable to accommodate the inhibitor in the active site (Figure 2) .
TF binding to FVII and FVIIa
In order to evaluate equilibrium parameters for the FVIIa-TF complex assembly in the absence of a macromolecular substrate, we exploited the increased efficiency of FVIIa amidolytic activity in the presence of TF. It has been described previously that dissociation constants that were calculated in the presence of either a peptidyl or macromolecular substrate were comparable [15] .
We compared the ability of R152Q FVII, V154G FVIIa or D343H FVIIa to displace functional FVIIa from the soluble TF-FVIIa complex with that of S344A FVIIa (Figure 3 ). R152Q FVII, V154G FVIIa and D343H FVIIa bound soluble TF with approx. 15-fold lower affinity as compared with S344A FVIIa (Table 2) . Similar K d values were calculated using soluble TF produced in either E. coli or P. pastoris. The assay performed in the absence of membranes gave similar results (not shown), supporting the hypothesis that phospholipids do not significantly influence the affinity of soluble TF for FVII\FVIIa [37] .
Both V154G FVIIa and R152Q FVII bound full-length TF, produced in E. coli and relipidated in PC (Figure 4) , with approx. 4-fold decreased affinity as compared with S344A FVIIa (Table  2) . Similar results were obtained using full-length TF made in insect cells. Because of sensitivity limitations, the fixed FVIIa concentration (5 nM) used in competition assays for binding to reconstituted TF was significantly higher than the inferred dissociation constant between FVIIa and TF. Therefore, calculated K d values may only provide an upper limit value of these constants, which, however, agree well with previous results [15] .
The dissociation constant that we measured for soluble TF and FVII (K d l 65.2p5.4 nM) was higher than previously reported [38] . This difference could explain the absence of autoactivation of FVII using concentrations of soluble TF and of FVII below the K d value that we determined [38] . Autoactivation occurs when the soluble TF-FVII concentration exceeds this K d value, indicating that, as already shown for relipidated TF [39] , FVII needs to be bound to soluble TF to be an appropriate substrate of the soluble TF-FVIIa enzymic complex.
In addition, the results shown in Table 2 suggest that the looser binding of all FVII forms to soluble TF, compared with full-length TF, amplifies the range of K d values, thus making soluble TF useful to estimate differences in TF binding among FVII forms.
DISCUSSION
Conversion of the zymogen FVII to fully active FVIIa has undergone extensive scrutiny, in part because of potential benefits that may be gained by a better understanding of the steps required to form enzymically active FVIIa [40] [41] [42] . After conversion into the two-chain form, FVIIa remains in a zymogenlike state that renders coagulation initiation dependent on TF exposure. Production of TF-independent FVIIa or the synthesis of inhibitors specific to FVIIa may result in improved strategies for treatment of haemorrhagic or thrombotic disorders [17, 18, 43, 44] .
Scheme 1 Effect of TF/PC binding to (A) S344A FVIIa and (B) V154G FVIIa with respect to salt-bridge formation
See the text for details.
Previous work has shown that the events leading to FVIIa catalytic enhancement include (i) interaction with TF, (ii) salt bridge formation between Ile"&$ and Asp$%$, and (iii) ordering of the activation domain. However, the mutual and tight linkage among these steps has hampered the precise determination of their chronological sequence. More importantly, the lack of efficient models to represent zymogen-like FVIIa has hindered clarification of the TF mechanism of catalytic enhancement in the FVIIa-TF complex.
In the present paper, we describe the naturally occurring FVII mutant protein V154G, which shows properties consistent with the proposed zymogen-like form of FVIIa, a form that exists between the zymogen FVII and fully active FVIIa and which does not present a salt bridge between Ile"&$ and Asp$%$ [7] . Since salt-bridge formation is expected to partially protect FVIIa from chemical modifications, the FVIIa carbamylation experiments suggest that the majority of V154G FVIIa molecules maintain a zymogen-like form even when associated with TF.
We propose that impairment of salt-bridge formation and\or stability in V154G FVIIa is due to the introduction of a glycine residue at position P2h producing a series of three glycine residues in a row (I"&$GGG) at the activation site. This sequence at the Nterminus should be extraordinarily flexible and could easily give rise to a variety of interchangeable structures, thus not favouring the insertion of the newly formed N-terminus into the protein. Consistent with this hypothesis, the V154A mutation did not impair the ability of the heavy chain N-terminus to form a salt bridge. Nevertheless, V154A FVIIa showed reduced catalytic efficiency compared with wild-type FVIIa, suggesting an important role of Val"&% in the conversion of FVIIa into a fully active enzyme.
The ' immature ' V154G FVIIa molecule was exploited to investigate the active-site competence of this salt-bridge-less form of FVIIa. Its inability to accommodate an active-site inhibitor, even at high FVIIa concentrations, would suggest that the specificity pocket is not properly formed. This result may help to interpret the low catalytic efficiency of FVIIa in the absence of TF as the predominance of an inactive zymogen-like form in the equilibrium after FVII cleavage at Arg"&#.
The V154G FVIIa variant, modelling a salt-bridge-less form of FVIIa, allowed us to analyse the binding of TF to this intermediate form of FVIIa, therefore representing a more physiological interaction between TF and FVIIa compared with previous studies [7, 16] . V154G FVIIa also differs from previously described FVIIa mutants that could be defined as zymogen-like FVIIa [9, 41] . These mutations either impaired the contact region between FVIIa and TF [41] , or had all the residues in Loop 170s replaced with those of trypsin [9] , thus not representing models to study the interaction of a salt-bridge-less FVII form with other macromolecules of interest in blood-clotting initiation.
To investigate TF binding to V154G FVIIa, we also used the FVII mutants R152Q, D343H and S344A to represent zymogen FVII, zymogen-like FVIIa, and inactive FVIIa respectively. V154G FVIIa bound soluble TF with an affinity comparable with that of mutants that lacked the salt bridge (R152Q and D343H). Schemes 1(A) and 1(B) depict binding of TF to mutant S344A and V154G FVIIa respectively, and provide models for interpreting the measured dissociation constants reported in Table 2 . In the presence of TF, the equilibrium may be shifted from a zymogen-like FVIIa (white) towards active FVIIa (grey) by TF preferential binding to the species that has already formed the Ile"&$-Asp$%$ salt bridge (K " jK # ). Alternatively, TF could bind zymogen-like FVIIa and active FVIIa with comparable affinity, without influencing their equilibrium, leading to an inactive and an active complex (lower left and lower right TF-FVIIa complexes), respectively. Conformational changes due to TF interaction with the zymogen-like form stabilize saltbridge formation and order the activation domain, giving rise to the active enzymic complex FVIIa-TF [(K # )j(K % jK $ )]. In the case of S344A FVIIa (Scheme 1A), the calculated dissociation constant (0.27 nM) between TF and FVIIa would reflect the combination of the equilibrium constants of all the steps involved in the two different pathways [K "
In contrast, binding of TF to V154G FVIIa (Scheme 1B), which retains characteristics of a zymogen-like form, would be insufficient to drive this FVIIa variant into the active conformation. In this case, the quasi-homogeneity, with respect to salt-bridge formation, of zymogen-like V154G FVIIa molecules and the negligible value of K $ would simplify the scheme to a single pathway. It is possible to assert, with a reasonable approximation, that the calculated dissociation constant (1.15 nM) represents the mere interaction of TF with the zymogen-like V154G FVIIa (K % ). Based on the comparison of dissociation constants between full-length TF and the different FVII species, and the above mentioned interpretation, the preferential TF binding to the active FVIIa form, as suggested by Bach et al. [24] , cannot account for the entire FVIIa catalytic enhancement by TF. Conformational changes driven by the interaction with TF must contribute to FVIIa conversion into the active form.
It is worth noting that the dissociation constants between active FVIIa and TF reconstituted in phospholipid vesicles calculated in this study agree well with previous investigations using bovine and human proteins [7, 15] , but differ from results obtained in non-equilibrium conditions [24] . The difference in affinity between FVII\FVIIa forms and TF (truncated or reconstituted forms) is consistent with previous reports [7, 24] and correlates well with the described tighter binding of TF to active site modified FVIIa [7] . However, these findings do not mirror results obtained by surface plasmon resonance, probably owing to the differences between experimental approaches [16] .
In the present study, we characterized a FVII mutant that, after cleavage, still shares characteristics with the FVII zymogen form, thus representing a model of the zymogen-like FVIIa not previously described. Since this form of FVIIa is predominant in the absence of TF, the interaction of V154G FVIIa with an active-site inhibitor and with TF mimics, to date, the most realistic interaction that triggers coagulation initiation.
